Investor Ab

Institutional investor · Portfolio as of Q2 2026

Q2 2026 Summary

Opened 1 position, exited 4, added to 2. Portfolio: $14.4B across 7 positions.

Top Holdings7 positions

Checking export access…
Activity:
AZN

AstraZeneca PLC

51.6M$9.8B67.9%$197.22-3.85%
2 qtrssince 2026-Q1
Unchanged
0
NDAQ

Nasdaq, Inc.

58.4M$4.6B32.0%$32.70+140.22%
27 qtrssince 2019-Q4
Increased
Unranked
MDWD

MediWound Ltd.

872,093$12.8M0.1%$18.06-18.60%
8 qtrssince 2024-Q3
Unchanged
0
CLBT

Cellebrite DI Ltd.

75,000$1.1M0.0%$14.00-19.56%
2 qtrssince 2026-Q1
Increased
36
MU

Micron Technology, Inc.

470$542,5160.0%$1,153.930.00%
1 qtr
New
37
VZ

Verizon Communications Inc.

11,300$478,4420.0%$47.88-14.39%
2 qtrssince 2026-Q1
Unchanged
0
BMRN

BioMarin Pharmaceutical Inc.

3,700$211,7140.0%$70.69-19.06%
6 qtrssince 2025-Q1
Unchanged
0
$14.4B
AUM
7
Positions
Q2 2026
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$4,434,976,044-1.83696518264%
2025-Q2$5,226,676,48617.8512901568%
2025-Q3$5,168,890,908-1.10558933875%
2025-Q4$5,674,166,4269.77531789688%
2026-Q1$15,124,585,250166.551667937%
2026-Q2$14,403,406,346-4.76825573779%
Activity profile
$ moved · Q2'26
New<1%Increased99%Decreased0%Exited1%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.2 years
<1Q0%1-4Q43%1-2Y0%2Y+57%

Investor Ab manages $14.4B across 7 positions as of Q2 2026. Top holdings: AZN (67.9%), NDAQ (32.0%), MDWD (0.1%). Fund DNA: Concentrated Value. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$14B
AZN67.92%
NDAQ31.98%
MDWD0.09%
CLBT0.01%
MU0.00%
VZ0.00%
BMRN0.00%
WHR0.00%
KYIV0.00%
CRSR0.00%

Portfolio allocation by GICS sector

Sectors4
Healthcare68.01%
Financial Services31.98%
Technology0.01%
Communication Services0.00%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Financial Services
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L33
Conviction38
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used